A #TextMessaging #mhealth–Based Program to Transition From Basal Insulin to Glucagon-Like Peptide-1 Receptor Agonists in Safety-Net Diabetes Care: Pilot Quality Improvement Intervention Study Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and basal insulin both lower blood sugar, but while insulin puts people at risk of hypoglycemia and weight gain, GLP-1 RAs do not. In addition, GLP-1 RAs have added cardiometabolic and renal benefits. For these reasons, when possible, many primary care providers prefer their patients with type 2 diabetes to be from basal insulin to a GLP-1 RA. This transition process can be labor intensive, requiring multiple dosing adjustments and a watchful eye for hypoglycemia and hyperglycemia. The Mobile Insulin Titration Intervention (MITI)–GLP1 program uses SMS #TextMessaging #mhealth–based technology to support a streamlined and supervised transition process from basal insulin to a GLP-1 RA. This program takes place at a multilingual safety-net clinic. Objective: Our objectives were to assess program #feasibility and acceptability to determine whether the intervention was doable, practical, and worthy of further investigation via a larger controlled trial. Preliminary clinical outcomes are also discussed in this paper. Methods: Patients were enrolled on a secure web platform that sent them a daily SMS text message asking the following: “What was your fasting blood sugar this morning?” Each weekday, texted responses containing patients’ fasting blood sugar levels were checked for alarm values, and once weekly, patients were called and advised on whether and how to lower their basal insulin and increase their GLP-1 RA dose. The program was co-run by general internal medicine physicians and nurses and continued until the patient had their insulin stopped completely and/or their GLP-1 RA dose reached the maximum, or 16 weeks elapsed. All enrolled patients were included in the analyses. Results: A total of 72 patients completed the pilot program. #feasibility and acceptability were high. Of 3671 SMS text messages sent by the program, 3520 (95.89%) received a response from patients. Of 719 cumulative weeks in which Thursday titration phone calls were attempted, successful connections with patients were made in 649 (90.26%) instances. Preliminary clinical outcomes were promising. Insulin doses were meaningfully reduced (55/72, 76.39% had their basal insulin reduced by at least 50%; 45/72, 62.5% had their insulin stopped completely). GLP-1 RA doses were meaningfully increased (64/72, 88.89% had their GLP-1 RA dose increased by ≥1 level; 45/72, 62.5% were discharged on the maximum dose of their GLP-1 RA). There was minimal hypoglycemia (5/3520, 0.14% of the SMS text messages reported a value of 400 mg/dL). Conclusions: A general internal medicine–run MITI-GLP1 pilot program using SMS #TextMessaging #mhealth and interdisciplinary teamwork between internists and nurses is a feasible and acceptable intervention for safely and effectively transitioning people with well-controlled type 2 diabetes away from basal insulin and toward a GLP-1 RA.

JMIR Formative Res: A #TextMessaging #mhealth–Based Program to Transition From Basal Insulin to Glucagon-Like Peptide-1 Receptor Agonists in Safety-Net Diabetes Care: Pilot Quality Improvement Intervention Study #DiabetesCare #GLP1RA #TextMessaging #mHealth #Insulin

GLP-1 Receptor Agonists.

www.nejm.org/doi/full/10....

@nejm.org
#CardioSky #MedSky #Cardiology #EndoSky #GLP1RA

📚 In this retrospective cohort study, GLP1-RA use was not associated with increased risk of pneumonia or other procedure-related complications among patients undergoing gastrointestinal endoscopy.
🔗 https://ow.ly/BnIv50YxQZq
🏷️ #GLP1RA

JAMA Cardiology presents "Oral Glucagon-Like Peptide-1 Therapies—Moving Beyond Needles," an Editor's Note by Sadiya S. Khan, MD, MSc1,2. Published online March 25, 2026. DOI: 10.1001/jamacardio.2026.0261. Includes links to author affiliations and article information.

💬 Editor's Note: Oral #GLP1RA therapies offer new options for cardiovascular risk reduction, supporting shared decision-making for patients and clinicians as the landscape evolves beyond injectable agents.

ja.ma/4dHrVRK

Sankey diagram showing medication switches. Semaglutide (Wegovy) 45 098 (35.5%), Semaglutide (Ozempic) 34 828 (27.4%), Liraglutide (Saxenda) 26 384 (20.8%), Tirzepatide 9866 (7.8%), Semaglutide (Rybelsus) 4619 (3.6%), Dulaglutide 4438 (3.5%).

Among adults with overweight or obesity, <25% remained on a #GLP1RA at 12 months. Switching agents was common and linked to higher persistence and adherence than remaining on one agent.

ja.ma/4sCgu1W

Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists This systematic review and meta-analysis quantifies the heterogeneity of treatment effects of glucagon-like peptide-1 receptor agonists, including semaglutide, liraglutide, exenatide, lixisenatide, an...

GLP-1RA producen una mayor pérdida del peso en las mujeres que en los hombres, con efectos consistentes en otras subpoblaciones #GLP1RA #sex jamanetwork.com/journals/jam...

GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes AbstractContext. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly prescribed to older adults with type 2 diabetes for their metabolic

Iniciar terapia con GLP-1RA en adultos mayores con diabetes tipo 2 se asocia con un riesgo moderadamente mayor de fracturas por fragilidad #GLP1RA #fractures academic.oup.com/jcem/article...

Kaplan-Meier curves compare the hazard of new chronic cough over time with Glucagon-Like Peptide-1 Receptor Agonist(GLP-1 RA). The graphs show cumulative incidence vs time for GLP1-RA against non-GLP1 receptor agonist,DPP-4 inhibitors,SGLT2 inhibitors and Sulfonylureas.

Use of glucagon-like peptide-1 receptor agonists (#GLP1RA) in adults with type 2 #diabetes was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.

bit.ly/4koi9We

GLP-1 Therapy Plus Progestin May Reduce Endometrial Cancer Risk in Some Patients In this cohort study, researchers aimed to examine endometrial cancer and hysterectomy patterns in patients who had endometrial hyperplasia or benign uterine pathology and were receiving progestins with or without GLP-1RAs or metformin.

For patients with endometrial hyperplasia or benign uterine pathology, receiving progestin in combination with #GLP1RA therapy is associated with a reduced risk of #endometrialCancer. Published in @jamanetworkopen.com.

https://bit.ly/4bOhdrR

#gyncsm #GLP1

GLP-1 RAs and Crohn’s Disease | Docwire News As reported at the 2026 Crohn’s and Colitis Congress, GLP-1 RAs are potentially beneficial as an adjunct to Crohn’s disease management for patients with overweight or obesity.

Real-world data presented at #CCCongress26 suggest #GLP1 RAs may benefit #CrohnsDisease patients with overweight/obesity. #GLP1RA use was linked to lower steroid dependence, fewer hospitalizations, and improved durability of advanced IBD therapy. #IBDSky #GISky

Effectiveness of Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists on Diabetic Foot Disease: An Emulated Target Trial: Annals of Internal Medicine: Vol 0, No 0 Background: The effects of sodium–glucose cotransporter-2 inhibitors (SGLT-2is) on diabetic foot disease have been mixed in prior trials of SGLT-2is compared with placebo. The comparative risk for dia...

Usuarios recientes de SGLT2i tienen un riesgo modestamente menor de enfermedad del pie principalmente por un menor riesgo de neuropatía que los que usan GLP-1RA #foot #SGLT2i #GLP1RA www.acpjournals.org/doi/10.7326/...

GLP-1 Use Lowers Colorectal Cancer Risk by a Third Compared to Aspirin Use The use of GLP-1 receptor antagonist therapy has led to a greater reduction in colorectal cancer incidence than has been observed with aspirin.

The use of GLP-1 receptor antagonist therapy has led to a greater reduction in #colorectalcancer incidence than has been observed with aspirin. Presented at #GI26.

https://bit.ly/45jGd6a

#crcsm #GLP1RA

Incretin-based therapies after bariatric surgery may protect against alcohol use disorder Use of incretin-based therapies may reduce the risk for alcohol use disorder in people who undergo Roux-en-Y gastric bypass or sleeve gastrectomy.

#MedNews - Use of incretin-based therapies may reduce the risk for alcohol use disorder in people who undergo Roux-en-Y gastric bypass or sleeve gastrectomy.

Full story 👉 buff.ly/tMu2y5R

#GLP1RA #BariatricSurgery

Three graphs show FM loss (A), FFM loss (B), and FFM to FM ratio (C) over time in months. Each graph compares "Surgery" and "GLP-1RA" treatments. Surgery shows higher FM loss and FFM to FM ratio but lower FFM loss compared to GLP-1RA.

Over 2 years, both bariatric surgery and #GLP1RA treatment were associated with substantial fat mass loss, moderate fat-free mass loss, and increased FFM/FM ratio, with changes more pronounced after surgery. ja.ma/3YQSXxH

Caregivers with #FoodInsecurity weighing #GLP1RA use for children with #Obesity cited experiences with lifestyle change, trust in medication safety, and personal values as central to treatment decisions. ja.ma/49l47PJ

GLP-1RAs in Neuroendocrine Tumors: The Scientists and the Clinicians Conundrums | Join us on Monday, January 12 at 5:00 PM ET to explore the emerging evidence on GLP-1 receptor agonist use in patients with neuroendocrine tumors: https://bit.ly/414QXRB #endocrinology #GLP1RA

Impact of Monotherapy and Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists on Exosomal and Non-Exosomal Microrna Signatures in Type 2 Diabetes Mellitus: A Systematic Review Diabetes drug boost? Review links GLP-1RAs to miRNA changes—improves T2DM outcomes. #Type2Diabetes #GLP1RA

Diabetes drug boost? Review links GLP-1RAs to miRNA changes—improves T2DM outcomes. #Type2Diabetes #GLP1RA
www.rimpacts.com/rd/p?c=10039... 📄DOI: doi.org/10.1186/s129...

JAMA Network Open Research Letter: Glucagonlike Peptide-1 Receptor Agonists and Asthma Risk in Adolescents With Obesity. By Yung-Chieh Huang, Ming-Chin Tsai, and Tim C. C. Lin. Published December 29, 2025.

This retrospective cohort study reported an association between #GLP1RA use and a lower risk of acute #asthma exacerbations in adolescents with #overweight or #obesity, suggesting a potential dual benefit for this population. ja.ma/4aImOQ1

GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and Immune-Related adverse events across cancer types in People with type 2 Diabetes: A Target-Trial ... To evaluate whether Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use at immune checkpoint inhibitor (ICI) start is associated with mortality, h…

🎉Our new research shows that #GLP1RA use at #ICI initiation is associated with lower mortality, fewer hospitalizations, and fewer immune-related adverse events in individuals with cancer and T2D.

www.sciencedirect.com/science/arti...

A #FIDELITY Analysis on #Finerenone With #SGLT2i and #GLP1RA in CKD

#VisualAbstract by Cristina Popa

www.kireports.org/article/S2468-0249(25)00...

GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and Immune-Related adverse events across cancer types in People with type 2 Diabetes: A Target-Trial ... To evaluate whether Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use at immune checkpoint inhibitor (ICI) start is associated with mortality, h…

🎉Our new research shows that #GLP1RA use at #ICI initiation is associated with lower mortality, fewer hospitalizations, and fewer immune-related adverse events in individuals with cancer and T2D.
www.sciencedirect.com/science/arti...

🎊Our new research shows pre-transplant #GLP1RA + #SGLT2i therapy is associated with lower post-transplant mortality, fewer graft failures, and complications in organ transplant candidates with obesity and T2D. advanced.onlinelibrary.wiley.com/doi/full/10....

Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes OBJECTIVE. Patients with type 2 diabetes (T2D) are at increased risk of acute pancreatitis (AP) and biliary events. Evidence remains mixed regarding the as

En pacientes con diabetes tipo 2, los GLP-1RA y los DPP-4i se asocian con un pequeño aumento en el riesgo de enfermedad biliar pero no de pancreatitis aguda, comparados con los SGLT2i #SGLT2is #GLP1RA #dpp4i #t2d diabetesjournals.org/care/article...

Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emul... This target trial emulation in solid organ transplant candidates with obesity and type 2 diabetes evaluates whether pre-transplant dual therapy with GLP-1 receptor agonists plus SGLT2 inhibitors is a....

Excited to share our new work using real world data and a target trial emulation to evaluate pre transplant dual therapy with #GLP1RA plus #SGLT2i in solid organ transplant candidates with #Obesity and #Type2Diabetes

advanced.onlinelibrary.wiley.com/doi/10.1002/...

Glucagon-Like Peptide-1 Receptor Agonists and Chronic Cough This cohort study examines the clinical association between glucagon-like peptide 1 receptor agonists and chronic cough.

Uso de GLP-1RA se asocia con tos crónica #chroniccough #GLP1RA jamanetwork.com/journals/jam...

Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation This cohort study examines gestational weight gain and pregnancy outcomes after glucagon-like peptide-1 (GLP-1) receptor agonist discontinuation.

En mujeres con obesidad, uso de GLP-1RA c/suspensión antes del embarazo o a principios del embarazo se asocia con más aumento del peso gestacional y mayor riesgo de parto pretérmino, diabetes gestacional y de trastornos hipertensivos del embarazo #pregnancy #GLP1RA jamanetwork.com/journals/jam...

GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study.
Chao, Lily C et al.
Paper
Details
#Type1Diabetes #GLP1RA #YouthHealth

Synergistic associations of metformin and GLP‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes Background Metformin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of adiposity-related cancers in patients with type 2 diabetes (T2D). The potential synergistic effe...

En pac c/diabetes tipo 2, TTO dual c/metformina y GLP-1RA se asocia c/incidencia 39% menor de neoplasias asoc c/adiposidad y mortalidad 67% menor, con un impacto notable sobre las variables relacionadas con el cáncer #T2D #metformin #GLP1RA #Cancer dom-pubs.onlinelibrary.wiley.com/doi/10.1111/...

Glucagon-Like Peptide-1 Receptor Agonists and Chronic Cough This cohort study examines the clinical association between glucagon-like peptide 1 receptor agonists and chronic cough.

Uso de agonistas del receptor del péptido 1 semejante a glucagon se asocia con tos crónica #GLP1RA #chroniccough jamanetwork.com/journals/jam...

Kaplan-Meier curves show the hazard of new chronic cough over time comparing GLP-1 RA with non-GLP-1 RA, DPP4, SGLT2 inhibitors, and sulfonylureas. Each graph plots 'Cumulative incidence of new chronic cough, %' against 'Time, d'. GLP1-RA shown with the other inhibitors.

Use of glucagon-like peptide-1 receptor agonists (#GLP1RA) in adults with type 2 #diabetes was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.

ja.ma/3LZtgrs